CRB-701

CRB-701 (SYS6002) is a next-generation antibody-drug conjugate (ADC) designed to target Nectin-4, a clinically validated tumor-associated antigen highly expressed in several solid tumors, including urothelial and cervical cancers. The drug consists of a novel anti-Nectin-4 monoclonal antibody linked via a site-specific, cleavable linker to the cytotoxic payload monomethyl auristatin E (MMAE), with a homogenous drug-antibody ratio of 2. This third-generation linker technology aims to reduce dose-limiting toxicities seen with earlier ADCs such as enfortumab vedotin by enabling more stable systemic circulation and efficient intra-tumoral drug release. CRB-701 is being developed primarily for advanced solid tumors expressing high levels of Nectin-4, including metastatic urothelial carcinoma and relapsed/refractory metastatic cervical cancer. It has received FDA fast track designation for relapsed/refractory metastatic cervical cancer and is currently under investigation in Phase 1/2 clinical trials in the US, UK, and China[1][3][5][6].

Other names

SYS6002SYS-6002SYS 6002CRB-701CRB701CRB 701